Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Breast Cancer Registry

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by iOMEDICO AG
Arbeitskreis Klinische Studien
Arbeitsgemeinschaft fur Internistische Onkologie
Information provided by (Responsible Party):
iOMEDICO AG Identifier:
First received: May 9, 2011
Last updated: July 9, 2014
Last verified: July 2014

The registry aims to collect and analyse information on the antineoplastic treatment of breast cancer in daily routine practice in Germany. The registry will follow up patients for three years. It will identify common sequences of treatments used as well as changes in the treatment of the disease. The impact of nutrition (MaNut) and physical activity (MaFit) on the course of the adjuvant disease will be examined, as well as long-term side effects of adjuvant treatment (MaTox). Health-related quality of life will be analysed during the course of the treatment (MaLife). Based on the available data a prognostic score will be developed.

Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Registry to Present Treatment and Sequences of Treatments in Routine Practice in Germany

Resource links provided by NLM:

Further study details as provided by iOMEDICO AG:

Primary Outcome Measures:
  • Course of Antineoplastic Treatment [ Time Frame: 5 years ] [ Designated as safety issue: No ]

Estimated Enrollment: 4500
Study Start Date: February 2007
Estimated Study Completion Date: December 2019
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Breast cancer patients undergoing antineoplastic or antihormonal therapy.


Inclusion Criteria:

  • Breast cancer
  • 18 years and older
  • Antineoplastic or antihormonal treatment

Exclusion Criteria:

  • No breast cancer
  • Below 18 years
  • No antineoplastic or antihormonal treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01351584

Contact: Lisa Kruggel +49 761 15242 - 0
Contact: Holger Hartmann, PhD +49 761 15242 - 0

iOMEDICO AG Recruiting
Freiburg, BW, Germany
Sponsors and Collaborators
Arbeitskreis Klinische Studien
Arbeitsgemeinschaft fur Internistische Onkologie
Study Chair: Hans Tesch, MD
  More Information

No publications provided

Responsible Party: iOMEDICO AG Identifier: NCT01351584     History of Changes
Other Study ID Numbers: IOM TMK, Tumorregister Mammakarzinom
Study First Received: May 9, 2011
Last Updated: July 9, 2014
Health Authority: Germany: Ethics Commission

Keywords provided by iOMEDICO AG:
Breast Cancer
Advanced Breast Cancer
Health Services Research
Palliative Treatment
Adjuvant Drug Therapy
Nutrition Assessment
Physical Activity

Additional relevant MeSH terms:
Breast Neoplasms
Breast Diseases
Neoplasms by Site
Skin Diseases processed this record on November 20, 2014